| abstract |
Novel amides of the general formula <FORM:1116433/C2/1> (wherein R3 and R4 each represent a halogen atom or a C1- 5 alkyl, alkylthio or alkylsulphonyl, di-(C1- 5 alkyl)-sulphamoyl, trihalomethyl, benzylthio, SH, NH2, di-(C1- 5 alkyl)-amino, CN, NO2, CONH2, di-(C1- 5 alkyl) -carbamoyl, C1- 6 alkanoylamino or phenyl radical, -X- represents -CH2-, -CH(CF3)-, -CR1R2-, where R1 is H and R2 is C1- 5 alkyl or haloalkyl or C2- 5 alkenyl or alkynyl or R1 and R2 together form a methylene, C2- 5 alkylidene or ethylene group, or -CR1R11-, where R1 is H and R11 is a halogen atom or a C1- 5 alkyl alkoxy group or R1 and R11 are both C1- 5 alkyl groups, and each of n and m is 0, 1 or 2 provided n + m is 1, 2 or 3, or may be zero when -X- is -CH(CF3)-) are prepared from the corresponding acids by the following processes: (a) (except when R3 or R4 is NH2, dialkylamino or CONH2) treating the acid with a thionyl or phosphorus halide in an inert solvent and reacting the resulting acid halide with a compound HN(Y)2, any substituent containing an active hydrogen atom being first protected by benzylation and subsequently regenerated by hydrogenation; or (b) reacting the acid with the compound HN(Y)2 in the presence of cyclohexylcarbodiimide or after reaction with isobutyl chloroformate. The amides of the invention are stated to have anti-inflammatory, antipyretic, analgesic, cholesterol inhibiting and fatty acid synthesis inhibiting activity, and they may be administered orally as tablets or capsules. |